JP2020529193A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529193A5 JP2020529193A5 JP2019571019A JP2019571019A JP2020529193A5 JP 2020529193 A5 JP2020529193 A5 JP 2020529193A5 JP 2019571019 A JP2019571019 A JP 2019571019A JP 2019571019 A JP2019571019 A JP 2019571019A JP 2020529193 A5 JP2020529193 A5 JP 2020529193A5
- Authority
- JP
- Japan
- Prior art keywords
- dna
- amount
- subject
- threshold
- previous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008186 active pharmaceutical agent Substances 0.000 claims 89
- 238000000034 method Methods 0.000 claims 29
- 206010052779 Transplant rejections Diseases 0.000 claims 12
- 230000001965 increasing effect Effects 0.000 claims 12
- 238000011282 treatment Methods 0.000 claims 12
- 230000001413 cellular effect Effects 0.000 claims 11
- 238000012360 testing method Methods 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 210000000056 organ Anatomy 0.000 claims 8
- 108700028369 Alleles Proteins 0.000 claims 7
- 238000012544 monitoring process Methods 0.000 claims 7
- 208000010496 Heart Arrest Diseases 0.000 claims 6
- 238000001574 biopsy Methods 0.000 claims 6
- 208000027418 Wounds and injury Diseases 0.000 claims 5
- 230000000747 cardiac effect Effects 0.000 claims 5
- 230000006378 damage Effects 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 208000014674 injury Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 238000007887 coronary angioplasty Methods 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 238000011269 treatment regimen Methods 0.000 claims 3
- 230000001512 anti-cytomegaloviral effect Effects 0.000 claims 2
- 229940030600 antihypertensive agent Drugs 0.000 claims 2
- 239000002220 antihypertensive agent Substances 0.000 claims 2
- 210000004351 coronary vessel Anatomy 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 238000012207 quantitative assay Methods 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 230000003409 anti-rejection Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000009826 distribution Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- -1 plasma Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000000250 revascularization Effects 0.000 claims 1
- 238000005070 sampling Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (27)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762522556P | 2017-06-20 | 2017-06-20 | |
| US201762522547P | 2017-06-20 | 2017-06-20 | |
| US201762522560P | 2017-06-20 | 2017-06-20 | |
| US62/522,547 | 2017-06-20 | ||
| US62/522,560 | 2017-06-20 | ||
| US62/522,556 | 2017-06-20 | ||
| US201762542787P | 2017-08-08 | 2017-08-08 | |
| US201762542790P | 2017-08-08 | 2017-08-08 | |
| US62/542,790 | 2017-08-08 | ||
| US62/542,787 | 2017-08-08 | ||
| US201762546798P | 2017-08-17 | 2017-08-17 | |
| US201762546848P | 2017-08-17 | 2017-08-17 | |
| US201762546872P | 2017-08-17 | 2017-08-17 | |
| US62/546,798 | 2017-08-17 | ||
| US62/546,848 | 2017-08-17 | ||
| US62/546,872 | 2017-08-17 | ||
| US201762571715P | 2017-10-12 | 2017-10-12 | |
| US201762571709P | 2017-10-12 | 2017-10-12 | |
| US62/571,709 | 2017-10-12 | ||
| US62/571,715 | 2017-10-12 | ||
| US201762576641P | 2017-10-24 | 2017-10-24 | |
| US62/576,641 | 2017-10-24 | ||
| US201862632960P | 2018-02-20 | 2018-02-20 | |
| US62/632,960 | 2018-02-20 | ||
| US201862653261P | 2018-04-05 | 2018-04-05 | |
| US62/653,261 | 2018-04-05 | ||
| PCT/US2018/038604 WO2018237078A1 (en) | 2017-06-20 | 2018-06-20 | Assessing conditions in transplant subjects using donor-specific cell-free dna |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020529193A JP2020529193A (ja) | 2020-10-08 |
| JP2020529193A5 true JP2020529193A5 (enExample) | 2021-07-29 |
Family
ID=63047415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571019A Pending JP2020529193A (ja) | 2017-06-20 | 2018-06-20 | ドナー特異的セルフリーｄｎａを用いる移植対象における状態の評価 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210139988A1 (enExample) |
| EP (1) | EP3642367A1 (enExample) |
| JP (1) | JP2020529193A (enExample) |
| CN (1) | CN111094593A (enExample) |
| AU (1) | AU2018288835A1 (enExample) |
| CA (1) | CA3067634A1 (enExample) |
| IL (1) | IL271458A (enExample) |
| WO (1) | WO2018237078A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| CA3207599A1 (en) | 2010-05-18 | 2011-11-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| BR112013020220B1 (pt) | 2011-02-09 | 2020-03-17 | Natera, Inc. | Método para determinar o estado de ploidia de um cromossomo em um feto em gestação |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| EP3134541B1 (en) | 2014-04-21 | 2020-08-19 | Natera, Inc. | Detecting copy number variations (cnv) of chromosomal segments in cancer |
| US20180173846A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
| RU2760913C2 (ru) | 2016-04-15 | 2021-12-01 | Натера, Инк. | Способы выявления рака легкого |
| WO2018067517A1 (en) | 2016-10-04 | 2018-04-12 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
| CA3067637A1 (en) | 2017-06-20 | 2018-12-27 | The Medical College Of Wisconsin, Inc. | Assessing transplant complication risk with total cell-free dna |
| US12084720B2 (en) | 2017-12-14 | 2024-09-10 | Natera, Inc. | Assessing graft suitability for transplantation |
| US12024738B2 (en) | 2018-04-14 | 2024-07-02 | Natera, Inc. | Methods for cancer detection and monitoring |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| WO2020206292A2 (en) * | 2019-04-03 | 2020-10-08 | The Medical College Of Wisconsin, Inc. | Assessing conditions in transplant subjects using donor-specific cell-free dna |
| US11931674B2 (en) | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
| WO2020247263A1 (en) | 2019-06-06 | 2020-12-10 | Natera, Inc. | Methods for detecting immune cell dna and monitoring immune system |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013509883A (ja) * | 2009-11-06 | 2013-03-21 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 臓器移植患者における移植片拒絶反応の非侵襲的診断方法 |
| WO2013159035A2 (en) * | 2012-04-19 | 2013-10-24 | Medical College Of Wisconsin, Inc. | Highly sensitive surveillance using detection of cell free dna |
| US20160376652A1 (en) * | 2013-09-06 | 2016-12-29 | Immucor Gti Diagnostics, Inc. | Compositions and methods for diagnosis and prediction of solid organ graft rejection |
| US20160258010A1 (en) * | 2013-10-18 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Allele specific pcr assay for detection of nucleotide variants |
| WO2015069933A1 (en) * | 2013-11-06 | 2015-05-14 | The Board Of Trustees Of The Leland Stanford Junior University | Circulating cell-free dna for diagnosis of transplant rejection |
| WO2016123698A1 (en) * | 2015-02-06 | 2016-08-11 | Uti Limited Partnership | Diagnostic assay for post-transplant assessment of potential rejection of donor organs |
| HK1252152A1 (zh) * | 2015-04-30 | 2019-05-17 | Medical College Of Wisconsin, Inc. | 用於評估無細胞dna的多重優化錯配擴增(moma)實時pcr |
-
2018
- 2018-06-20 CN CN201880049767.XA patent/CN111094593A/zh active Pending
- 2018-06-20 JP JP2019571019A patent/JP2020529193A/ja active Pending
- 2018-06-20 AU AU2018288835A patent/AU2018288835A1/en not_active Abandoned
- 2018-06-20 EP EP18747030.7A patent/EP3642367A1/en active Pending
- 2018-06-20 CA CA3067634A patent/CA3067634A1/en active Pending
- 2018-06-20 WO PCT/US2018/038604 patent/WO2018237078A1/en not_active Ceased
- 2018-06-20 US US16/623,719 patent/US20210139988A1/en active Pending
-
2019
- 2019-12-16 IL IL271458A patent/IL271458A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529193A5 (enExample) | ||
| JP2020524519A5 (enExample) | ||
| JP2020529194A5 (enExample) | ||
| Iwai et al. | The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes | |
| Azakie et al. | Improving outcomes of the Fontan operation in children with atrial isomerism and heterotaxy syndromes | |
| Stallwood et al. | Acute renal failure in coronary artery bypass surgery: independent effect of cardiopulmonary bypass | |
| JP2020529193A (ja) | ドナー特異的セルフリーｄｎａを用いる移植対象における状態の評価 | |
| Aziz et al. | Transforming growth factor β in relation to cardiac allograft vasculopathy after heart transplantation | |
| van SUYLEN et al. | The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease | |
| Bonaccorsi-Riani et al. | Molecular characterization of acute cellular rejection occurring during intentional immunosuppression withdrawal in liver transplantation | |
| Beller et al. | Does preoperative troponin level impact outcomes after coronary artery bypass grafting? | |
| Azzawi et al. | Tumor necrosis factor-alpha gene polymorphism and death due to acute cellular rejection in a subgroup of heart transplant recipients | |
| Chopra et al. | Emerging role of cell-free DNA in kidney transplantation | |
| Richmond et al. | Validation of donor fraction cell-free DNA with biopsy-proven cardiac allograft rejection in children and adults | |
| Kanamori et al. | Noninvasive graft monitoring using donor‐derived cell‐free DNA in Japanese liver transplantation | |
| Harskamp et al. | Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery | |
| Snijders et al. | Molecular analysis of renal allograft biopsies: where do we stand and where are we going? | |
| Doucet et al. | Outcomes of left main revascularization in patients with acute coronary syndromes and stable ischemic heart disease: analysis from the EXCEL trial | |
| Angelini et al. | Discordance between pre and post cardiac transplant diagnosis: implications for pre-and postoperative decision making | |
| Corti et al. | Potential of real-time PCR assessment of granzyme B and perforin up-regulation for rejection monitoring in intestinal transplant recipients | |
| Mohamed et al. | Donor kidney evaluation | |
| Asad et al. | Role of Duke treadmill score in assessing the severity of coronary artery disease in patients presenting with angina | |
| KR102067610B1 (ko) | 급성관상동맥증후군 장기예후 검사방법 및 진단키트 | |
| Bahniwal et al. | Diagnostic approach to elevated dd-cfDNA with reassuring EMB in heart transplantation | |
| WO2020132349A2 (en) | Optimizing detection of transplant injury by donor-derived cell-free dna |